RecruitingPhase 2NCT07552168
INSPIRE: INnovative SABR for Prostate Cancer All IREland
Sponsor
Cancer Trials Ireland
Enrollment
136 participants
Start Date
Apr 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria19
- Written informed consent obtained prior to any study-related procedures
- Males ≥ 18 years of age
- ECOG performance status (PS) 0-2
- Biopsy-proven prostate adenocarcinoma without neuro-endocrine differentiation (within 18 months prior to registration, unless on active surveillance and re-biopsy not clinically indicated)
- Gleason score ≤ 4+3
- Clinical and/or MRI stage T1c-T3a, N0-X, M0-X
- PSA ≤ 30 ng/ml (within 60 days prior to registration / prior to starting androgen-deprivation therapy (ADT/hormone therapy) \[PSA ≤ 15 ng/ml for patients on 5-alpha reductase inhibitors\]
- Patients belonging to one of the following risk groups:
- Low risk - patients meeting all of the following criteria:
- Gleason ≤ 6
- Clinical stage T1c-T2a
- PSA < 10 ng/ml (within 60 days prior to registration)
- Intermediate risk - patients meeting any of the following criteria, assuming no high-risk features apply:
- Gleason 7 (3+4 or 4+3)
- MRI stage T2b-T2c (N0, M0-X)
- PSA 10-20 ng/ml (within 60 days prior to registration)
- High risk - patients with tumours that meet a maximum of one of the following criteria:
- MRI stage T3a (N0, M0)
- PSA >20 - ≤30 ng/ml (within 60 days prior to registration)
Exclusion Criteria8
- Previous malignancy within the last 2 years (except basal cell carcinoma (BCC) or squamous carcinoma of the skin), or if previous malignancy is expected to significantly compromise 5 year survival
- Prior pelvic radiotherapy
- Any prior active treatment for prostate cancer (with the exception of ADT). Patients previously on active surveillance are eligible if they continue to meet all other eligibility criteria.
- Life expectancy <5 years.
- Bilateral hip prostheses or any other implants/hardware that would introduce substantial CT artefacts
- Medical conditions likely to make radiotherapy inadvisable e.g. inflammatory bowel disease, significant urinary symptoms.
- Anticoagulation with warfarin/bleeding tendency making fiducial placement or surgery unsafe in the opinion of the clinician. Note: Anti-platelet agents e.g. aspirin, clopidogrel and DOACs such as apixaban, rivaroxaban are not contraindications to trial entry.
- Participation in another concurrent treatment protocol for prostate cancer (not including QoL, survivorship, exercise or registry studies).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
RADIATIONNext generation Stereotactic Ablative Radiotherapy (SABR)
Treatment will prioritise the dominant intraprostatic lesion (DIL) while sparing surrounding organs at risk (OARs).
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07552168
Related Trials
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
NCT056108521 location
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT04134260347 locations
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213398 locations
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
NCT058320863 locations
Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer
NCT038804221 location